MusclePharm (MSLPQ) 10-Q 9 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 01, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	MSLP
Entity Registrant Name	MusclePharm Corp
Entity Central Index Key	1,415,684
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,834,680

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 13,052	$ 7,081
Accounts receivable, net of allowance for doubtful accounts of $299 and $347 as of June 30, 2016 and December 31, 2015	20,217	22,003
Inventory	6,941	12,549
Prepaid giveaways	112	307
Prepaid stock compensation		1,641
Prepaid expenses and other current assets	4,467	3,698
Total current assets	44,789	47,279
Property and equipment, net	3,886	6,693
Investments, long-term		977
Intangible assets, net	1,798	8,652
Other assets	154	180
TOTAL ASSETS	50,627	63,781
Current liabilities:
Accounts payable	39,098	39,652
Accrued liabilities	11,538	12,526
Accrued restructuring charges, current	1,267	9,140
Obligation under secured borrowing arrangement	7,361
Convertible note with a related party, net of discount	5,976
Line of credit		3,000
Term loan		2,949
Other debt obligations	11	21
Total current liabilities	65,251	67,288
Convertible note with a related party, net of discount		5,952
Accrued restructuring charges, long-term	242	279
Other long-term liabilities	137	330
Total liabilities	65,630	73,849
Commitments and contingencies (Note 10)
Stockholders' deficit:
Common stock, par value of $0.001 per share; 100,000,000 shares authorized as of June 30, 2016 and December 31, 2015; 14,710,301 and 14,664,161 shares issued as of June 30, 2016 and December 31, 2015; 13,834,680 and 13,788,540 shares outstanding as of June 30, 2016 and December 31, 2015	14	14
Additional paid-in capital	153,506	147,646
Treasury stock, at cost; 875,621 shares as of June 30, 2016 and December 31, 2015	(10,039)	(10,039)
Accumulated other comprehensive loss	(166)	(172)
Accumulated deficit	(158,318)	(147,517)
TOTAL STOCKHOLDERS' DEFICIT	(15,003)	(10,068)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 50,627	$ 63,781

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 299	$ 347
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	14,710,301	14,664,161
Common Stock, shares outstanding	13,834,680	13,788,540
Treasury Stock, shares	875,621	875,621

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue, net		$ 32,867	$ 50,476	$ 75,779	$ 91,798
Cost of revenue	[1]	22,181	32,978	49,880	59,916
Gross profit		10,686	17,498	25,899	31,882
Operating expenses:
Advertising and promotion		2,686	8,285	6,973	15,510
Salaries and benefits		3,292	7,763	12,912	14,824
Selling, general and administrative		4,424	5,121	8,667	10,083
Research and development		531	921	1,394	1,886
Professional fees		1,742	2,064	3,130	3,519
Restructuring and other charges		(4,820)		(4,246)
Impairment of assets		4,313		4,313
Total operating expenses		12,168	24,154	33,143	45,822
Loss from operations		(1,482)	(6,656)	(7,244)	(13,940)
Loss on sale of subsidiary		(2,115)		(2,115)
Other expense, net		(592)	(348)	(1,304)	(531)
Loss before provision for income taxes		(4,189)	(7,004)	(10,663)	(14,471)
Provision for income taxes		7	21	138	33
Net loss		$ (4,196)	$ (7,025)	$ (10,801)	$ (14,504)
Net loss per share, basic and diluted		$ (0.30)	$ (0.51)	$ (0.78)	$ (1.08)
Weighted average shares used to compute net loss per share, basic and diluted		13,874,209	13,647,267	13,855,754	13,491,433
[1]	Cost of revenue for the three and six months ended June 30, 2016 included restructuring charges of $0.5 million and $2.2 million, respectively, related to write-down of inventory for discontinued products.

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Restructuring charges	$ 500,000	$ 0	$ 2,169,000	$ 0

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,196)	$ (7,025)	$ (10,801)	$ (14,504)
Other comprehensive loss:
Change in foreign currency translation adjustment	11	(97)	6	(177)
Comprehensive loss	$ (4,185)	$ (7,122)	$ (10,795)	$ (14,681)

Condensed Consolidated Stateme7

Condensed Consolidated Statement of Stockholder's Deficit (Unaudited) - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ (10,068)	$ 14	$ 147,646	$ (10,039)	$ (172)	$ (147,517)
Balance (in shares) at Dec. 31, 2015	13,788,540	13,788,540
Stock-based compensation related to issuance of common stock warrants to third parties for services	$ 6		6
Stock-based compensation	1,142		1,142
Stock-based compensation (in shares)		179,140
Stock-based compensation related to accelerated vesting of restricted stock awards to a terminated executive	3,900		3,900
Stock-based compensation related to accelerated vesting of restricted stock awards to terminated employees as part of restructuring	117		117
Stock-based compensation related to issuance of stock options to an executive and a director	55		55
Issuance of shares of common stock related to sale of subsidiary	640	$ 640	640
Issuance of shares of common stock related to sale of subsidiary (in shares)		200,000
Cancellation of executive restricted stock	0	$ 0	0	0	0	0
Cancellation of executive restricted stock (in shares)		(333,000)
Change in foreign currency translation adjustment	6				6
Net loss	(10,801)					(10,801)
Balance at Jun. 30, 2016	$ (15,003)	$ 14	$ 153,506	$ (10,039)	$ (166)	$ (158,318)
Balance (in shares) at Jun. 30, 2016	13,834,680	13,834,680

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,801,000)	$ (14,504,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation of property and equipment	816,000	838,000
Amortization of intangible assets	416,000	498,000
Provision for doubtful accounts	9,000	98,000
Loss on disposal of property and equipment	117,000	7,000
Loss on sale of subsidiary	2,115,000
Impairment of assets	4,313,000
Non-cash restructuring and other charges	(4,607,000)
Inventory write down related to restructuring	2,169,000	0
Amortization of prepaid stock compensation	938,000	2,236,000
Amortization of prepaid sponsorship and endorsement fees	844,000	3,252,000
Amortization of debt discount and issuance costs	24,000	19,000
Stock-based compensation	5,097,000	6,536,000
Issuance of common stock warrants to third parties for services	6,000	50,000
Changes in operating assets and liabilities:
Accounts receivable	952,000	(8,061,000)
Inventory	1,359,000	6,219,000
Prepaid giveaways	196,000	331,000
Prepaid sponsorship and endorsement fees		(3,462,000)
Prepaid expenses and other current assets	(260,000)	(1,857,000)
Other assets	(55,000)	(127,000)
Accounts payable and accrued liabilities	(1,173,000)	12,116,000
Accrued restructuring charges	(3,161,000)
Net cash (used in) provided by operating activities	(686,000)	4,189,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(378,000)	(851,000)
Proceeds from disposal of property and equipment	40,000	447,000
Proceeds from sale of subsidiary	5,942,000
Purchase of MusclePharm Apparel Rights		(850,000)
Trademark registrations	(154,000)	(87,000)
Investment in contract manufacturer		(977,000)
Net cash provided by (used in) investing activities	5,450,000	(2,318,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from line of credit		4,001,000
Payments on line of credit	(3,000,000)	(6,001,000)
Repayments of term loan	(2,949,000)	(415,000)
Proceeds from issuance of term loan		4,000,000
Issuance costs of term loan		(40,000)
Proceeds from secured borrowing arrangement, net of reserves	38,041,000
Payments on secured borrowing arrangement, net of fees	(30,791,000)
Repayments of other debt obligations	(10,000)	(25,000)
Repayment of capital lease obligations	(71,000)	(64,000)
Net cash provided by financing activities	1,220,000	1,456,000
Effect of exchange rate changes on cash	(13,000)	(177,000)
NET INCREASE IN CASH	5,971,000	3,150,000
CASH - BEGINNING OF PERIOD	7,081,000	1,020,000
CASH - END OF PERIOD	13,052,000	4,170,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	926,000	54,000
Cash paid for taxes	113,000	270,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment acquired in conjunction with capital leases	24,000	359,000
Purchase of property and equipment included in accounts payable and accrued liabilities	40,000	283,000
Trademark registration included in accounts payable and accrued liabilities		66,000
Biozone [Member]
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Loss on sale of subsidiary	2,115,000
Changes in operating assets and liabilities:
Inventory	(1,800,000)
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Shares of common stock issued in conjunction with BioZone disposition	$ 640,000
Muscle Pharm Apparel [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Shares of common stock issued in conjunction with MusclePharm Apparel rights acquisition		$ 1,394,000

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Description of Business MusclePharm Corporation, or the Company, was incorporated in Nevada in 2006. The Company is a scientifically driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company is headquartered in Denver, Colorado and, as of June 30, 2016, had the following wholly-owned operating subsidiaries: MusclePharm Canada Enterprises Corp (“MusclePharm Canada”), MusclePharm Ireland Limited (“MusclePharm Ireland”) and MusclePharm Australia Pty Limited (“MusclePharm Australia”). A former subsidiary of the Company, BioZone Laboratories, Inc. (“BioZone”), was sold on May 9, 2016. On August 24, 2015, the Board of Directors approved a restructuring plan for the Company. The approved restructuring plan was designed to reduce costs and to better align the Company’s resources for profitable growth. Specifically, through June 30, 2016, the restructuring plan resulted in: 1) reducing the Company’s workforce; 2) abandoning certain leased facilities; 3) renegotiating or terminating a number of contracts with endorsers in a strategic shift away from such arrangements and toward more cost effective marketing and advertising efforts; 4) discontinuing a number of stock keeping units (“SKUs”) and writing down inventory to net realizable value, or to zero in cases where the product was discontinued; and 5) writing off certain assets. Management is continuing to execute on the approved restructuring plan, and as such, additional restructuring charges may be necessary. See Note 4 for further detail. Management’s Plans with Respect to Liquidity and Capital Resources The Company’s management believes the restructuring plan implemented during August 2015, the reduction in ongoing operating costs and expense controls and the sale of BioZone, as further described in Note 6, may enable the Company ultimately to be profitable. However, the Company may need to continue to raise capital. There can be no assurance that such capital will be available on acceptable terms or at all. As of June 30, 2016, the Company had an accumulated deficit of $158.3 million and recurring losses from operations. The Company may incur additional losses until such time it can generate significant revenues and/or reduce operating costs. In September 2014, the Company borrowed $8.0 million under a line of credit with a bank. In February 2015, the Company entered into a term loan agreement with the same bank and borrowed $4.0 million. In December 2015, the Company received $6.0 million upon the issuance of a convertible note with a related party. In January 2016, the Company entered into a secured borrowing arrangement and received $49.3 million in gross borrowings during the six months ended June 30, 2016, of which $31.3 million was subsequently repaid on or prior to June 30, 2016. The Company has the ability to borrow up to $10.0 million subject to sufficient amounts of accounts receivable to secure the loan. As of June 30, 2016, the Company had approximately $13.1 million in cash and $20.5 million in working capital deficit. The accompanying condensed consolidated financial statements for the three and six months ended June 30, 2016 were prepared on the basis of a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. Accordingly, they do not give effect to adjustments that would be necessary should the Company be required to liquidate its assets. The Company has not established an ongoing source of revenue sufficient to cover its operating costs for at least the next 12 months in order to continue as a going concern. The ability of the Company to meet its total liabilities of $65.5 million as of June 30, 2016, and to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its commercial activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of these uncertainties.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The condensed consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these statements do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited interim condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of June 30, 2016, our results of operations for the three and six months ended June 30, 2016 and 2015, and our cash flows for the six months ended June 30, 2016 and 2015. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 17, 2016. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and tax assets, the assessment of useful lives, recoverability and valuation of long-lived assets, likelihood and range of possible losses on contingencies, restructuring liabilities, valuations of equity securities and intangible assets, fair value of derivatives, warrants and options, among others. Actual results could differ from those estimates. Stock-Based Compensation The Company estimates the fair value of employee stock options on the date of grant using the Black-Scholes option-pricing model. The determination of the fair value of each stock award using this option-pricing model is affected by the Company’s assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards and the expected term of the awards based on an analysis of the actual and projected employee stock option exercise behaviors and the contractual term of the awards. The Company recognizes stock-based compensation expense over the requisite service period, which is generally consistent with the vesting of the awards, based on the estimated fair value of all stock-based payments issued to employees and directors that are expected to vest. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition- Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3. Fair Value of Financial Instruments Management believes the fair value of the obligation under secured borrowing arrangement and convertible note with a related party approximates carrying value because the debt carries market rates of interest. The Company’s remaining financial instruments consisted primarily of accounts receivable, accounts payable, accrued liabilities, and accrued restructuring charges, all of which are short-term in nature with fair values approximating carrying value.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Restructuring	Note 4. Restructuring As part of an effort to better focus and align the Company’s resources toward profitable growth, on August 24, 2015, the Board of Directors authorized the Company to undertake steps to commence a restructuring of the business and operations, which continued through the current quarter. The Company closed certain facilities, reduced headcount, discontinued products, and renegotiated certain contracts resulting in restructuring and other charges of $21.2 million in 2015, of which $3.0 million was included in cost of revenue and $18.3 million was included in operating expenses in the condensed consolidated statements of operations for the year ended December 31, 2015. For the three and six months ended June 30, 2016, the Company recorded restructuring charges of $0.5 million and $2.2 million, respectively, that were related to the write-down of inventory identified to be discontinued in the restructuring plan, and included in cost of revenue. For the three months ended June 30, 2016, the Company recorded a credit in restructuring and other charges of $4.8 million comprised of an expense credit of $4.8 million and the release of restructuring accrual of $7.0 million, offset by the cash payment of $2.2 million related to the settlement agreement which terminated all future commitments between ETW Corporation (“ETW”) and the Company (see Note 14). For the six months ended June 30, 2016, the Company recorded a credit in restructuring and other charges of $4.2 million comprised of: (i) an expense credit of $4.8 million and the release of restructuring accrual of $7.0 million, offset by the cash payment of $2.2 million related to the settlement agreement which terminated all future commitments between ETW and the Company (see Note 14); $0.4 million to be paid in cash which related to employee severance costs; (ii) $0.1 million for other non-cash charges which related to acceleration of stock-based compensation of terminated employees; and (iii) $0.1 million related to write-off of long-lived assets related to the abandonment of certain lease facilities. The Company anticipates incurring additional restructuring charges for the remainder of 2016 to continue to move the business toward profitable operations. As of June 30, 2016, the restructuring charges to be paid in cash totaled $1.5 million, which are comprised of: (i) $22,000 related to severance and termination benefit costs related to terminated employees; (ii) $1.0 million related to cancellation of certain contracts and sponsorship agreements, which are payable through December 2016; (iii) $0.2 million related to purchase commitment of discontinued inventories not yet received by the Company, which remained accrued as of June 30, 2016; and (iv) $0.3 million for costs associated with permanently vacating certain leased facilities. The following table illustrates the provision of the restructuring charges and the accrued restructuring charges balance as of June 30, 2016 and December 31, 2015 (in thousands): Employee Severance Costs Contract Termination Costs Purchase Commitment of Discontinued Inventories Not Yet Received Abandoned Lease Facilities Total Balance as of December 31, 2014 $ — $ — $ — $ — $ — Expensed 1,353 6,979 350 467 9,149 Cash payments (845 ) (949 ) — (56 ) (1,850 ) Reclassification from accounts payable to restructuring charges — 2,120 — — 2,120 Balance as of December 31, 2015 508 8,150 350 411 9,419 Expensed 410 — — (51 ) 359 Benefit from settlement of Endorsement Agreement with ETW — (4,750 ) — — (4,750 ) Cash payments (896 ) (2,366 ) (175 ) (82 ) (3,519 ) Balance as of June 30, 2016 $ 22 $ 1,034 $ 175 $ 278 $ 1,509 The total future payments under the restructuring plan as of June 30, 2016 are as follows (in thousands): Year Ending December 31, Outstanding Payments Remainder of 2016 2017 2018 2019 2020 2021 Total Contract termination costs $ 1,034 $ — $ — $ — $ — $ — $ 1,034 Purchase commitment of discontinued inventories not yet received 175 — — — — — 175 Employee severance costs 22 — — — — — 22 Abandoned leased facilities 36 75 77 79 11 — 278 Total future payments $ 1,267 $ 75 $ 77 $ 79 $ 11 $ — $ 1,509

Capstone Nutrition Agreements

Capstone Nutrition Agreements	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capstone Nutrition Agreements	Note 5. Capstone Nutrition Agreements The Company entered into a series of agreements with Capstone Nutrition (“Capstone”) effective March 2, 2015, including an amendment (the “Amendment”) to a Manufacturing Agreement dated November 27, 2013 (as amended, the “Manufacturing Agreement”). Pursuant to the Amendment, Capstone shall be the Company’s nonexclusive manufacturer of dietary supplements and food products sold or intended to be sold by the Company. The Amendment includes various agreements including amended pricing terms. The initial term ends January 1, 2022, and may be extended for three successive 24-month terms, and includes renewal options. The Company agreed to pay to Capstone a non-refundable sum of $2.5 million to be used by Capstone solely in connection with the expansion of its facility necessary to fulfill anticipated Company requirements under the Manufacturing Agreement and Amendment. The Company paid Capstone this $2.5 million during 2015. The Company and Capstone entered into a Class B Common Stock Warrant Purchase Agreement (“Warrant Agreement”) whereby the Company may purchase approximately 19.9% of Capstone’s parent company, INI Parent, Inc. (“INI”), on a fully-diluted basis as of March 2, 2015. Pursuant to the Warrant Agreement, INI issued to the Company a warrant (the “Warrant”) to purchase shares of INI’s Class B common stock, par value $0.001 per share, at an exercise price of $0.01 per share (the “Warrant Shares”). The warrant may be exercised if the Company is in compliance with the terms and conditions of the Amendment. The Company utilized the Black-Scholes valuation model to determine the value of the warrants and recorded an asset of $977,000, which was accounted for under the cost method and assessed for impairment. The warrant was included in long-term investments on the consolidated balance sheet as of December 31, 2015. However, during the three months ended June 30, 2016, the Company reassessed the value of the warrant and considered it to be fully impaired as the Company no longer believes there is any remaining value to the warrant. The Company also had recorded $1.5 million of prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2015, which were being amortized over the remaining life of the Manufacturing Agreement of 6.5 years. However, during the three months ended June 30, 2016, the Company reassessed the Manufacturing Agreement, which was the basis of the prepaid asset, and considered the entire remaining balance of $1.4 million impaired as the Company no longer believes there is any remaining value to the Manufacturing Agreement. These conclusions were based in large part on the fact that Capstone sold its primary powder manufacturing facility during the quarter ended June 30, 2016, which significantly reduced its manufacturing capacity, and the ongoing dispute which is discussed below. In total, the Company recognized $2.4 million of impairment expense during the three months ended June 30, 2016 related to previously recorded Capstone-related assets. The Company and INI also entered into an option agreement (the “Option Agreement”). Subject to additional provisions and conditions set forth in the Option Agreement, at any time on or prior to June 30, 2016, the Company shall have the right to purchase for cash all of the remaining outstanding shares of INI’s common stock not already owned by the Company after giving effect to the exercise of the Warrant, based on an aggregate enterprise value, equal to $200.0 million. The fair value of the option was deemed de minimis as of the transaction date. The Company did not exercise the option to purchase the remaining outstanding shares of INI’s common stock and such option expired on June 30, 2016. The Company is engaged in a dispute with Capstone concerning amounts allegedly owed under the Manufacturing Agreement. Capstone claims that it is owed approximately $22.0 million of outstanding accounts payable, of which $20.7 million was included in the Company’s accounts payable balance as of June 30, 2016. The companies are working to reconcile the $1.3 million variance which relates to invoices not received by the Company as well as questions about shipping and receiving documentation to support potentially open invoices as claimed by Capstone. The Company claims that Capstone owes the Company at least $13.5 million in losses caused by, among other things, Capstone’s failure to timely manufacture and supply the Company’s products. In February 2016, Capstone requested a mediation with the American Arbitration Association which was held in May 2016 in New York. The mediation did not result in resolution to this matter. As of June 30, 2016, Capstone has filed suit against the Company and the Company has filed countersuit in response. The Company alleges that Capstone, and its parent company INI, collaborated to intentionally harm its business and was, and still is, unable to fill orders placed by the Company.

Sale of BioZone

Sale of BioZone	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Sale of BioZone	Note 6. Sale of BioZone In May 2016, the Company completed the sale of its wholly-owned subsidiary, BioZone, for gross proceeds of $9.8 million, including cash of $5.9 million, a $2.0 million credit for future inventory deliveries reflected as a prepaid asset in the condensed consolidated balance sheets and $1.5 million which is subject to an earn-out based on the financial performance of BioZone for the twelve months following the closing of the transaction. In addition, the Company agreed to pay down $350,000 of BioZone’s accounts payables, which was deducted from the purchase price. As part of the transaction, the Company also agreed to transfer to the buyer 200,000 shares of its common stock with a market value on the date of issuance of $640,000, for consideration of $50,000. The Company recorded a loss of $2.1 million related to the sale of BioZone. The loss on the sale of BioZone primarily related to the subsidiary’s pre-tax losses for 2016. Pre-tax loss for BioZone for the three and six months ended June 30, 2016 was $0.5 million and $1.5 million, respectively. Upon closing of the sale of BioZone, the Company entered into a manufacturing and supply agreement whereby the Company is required to purchase a minimum of $3.0 million of products from BioZone annually for an initial term of three years. The sale of BioZone did not qualify as discontinued operations as the disposal of BioZone did not represent a strategic shift that had (or will have) a major effect on the Company’s operations and financial results. The following table summarizes the components of the loss from the sale of BioZone (in thousands): Cash proceeds from sale $ 5,942 Consideration for common stock transferred 50 Prepaid inventory 2,000 Fair market value of the common stock transferred (640 ) Assets sold: Accounts receivable, net (923 ) Inventory, net (1,761 ) Fixed assets, net (2,003 ) Intangible assets, net (5,657 ) All other assets (41 ) Liabilities transferred 1,197 Transaction and other costs (279 ) Loss on sale of subsidiary $ (2,115 ) In connection with the sale of BioZone, the Company and BioZone entered into a transition services agreement to provide administrative support, and a sub-lease for certain premises. The Company also entered into a product development and supply agreement with Flavor Producers, Inc. (“FPI”), the parent company of the buyer, to develop certain products to be sold by the Company. If the product development effort is successful, the minimum purchase commitment under the product development and supply agreement with FPI is $3.0 million over the term of 12 months. Pursuant to the agreement, product pricing is fixed for one year, and was negotiated as an arms-length transaction.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Note 7. Balance Sheet Components Inventory Inventory consisted of the following as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, Raw materials $ — $ 1,385 Work-in-process — 22 Finished goods 6,941 11,142 Inventory $ 6,941 $ 12,549 The Company writes down inventory for obsolete and slow moving inventory based on the age of the product as determined by the expiration date. Products within one year of their expiration dates are considered for write-off purposes. Historically, the Company has had minimal returns with established customers. Other than write-down of inventory during restructuring activities, the Company incurred insignificant inventory write-offs during the three and six months ended June 30, 2016 and 2015. In May 2016, the Company completed the sale of BioZone, which resulted in a reduction of inventory of $1.8 million. See additional information in Note 6. As disclosed further in Note 4, the Company executed a restructuring plan in August 2015 and wrote down inventory related to discontinued products. The write-down of inventory of $0.5 million and $2.2 million is included as a component of Cost of revenue in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2016, respectively. Additionally, $0.4 million of inventory related to the Arnold Schwarzenegger product line was considered impaired, and included as a component of the Impairment of assets in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2016, see additional information in Note 14. There were no such write-downs for the three or six months ended June 30, 2015. Inventory write-downs, once established, are not reversed as they establish a new cost basis for the inventory. Property and Equipment Property and equipment consisted of the following as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, Furniture, fixtures and equipment $ 3,803 $ 3,621 Leasehold improvements 2,519 3,227 Manufacturing and lab equipment 13 1,659 Vehicles 653 1,146 Displays 486 483 Website 458 463 Construction in process 41 54 Property and equipment, gross 7,973 10,653 Less: accumulated depreciation and amortization (4,087 ) (3,960 ) Property and equipment, net $ 3,886 $ 6,693 Depreciation and amortization expense related to property and equipment was $389,000 and $456,000 for the three months ended June 30, 2016 and 2015, respectively, and $816,000 and $838,000 for the six months ended June 30, 2016 and 2015, respectively, which is included in the selling, general, and administrative expense in the accompanying condensed consolidated statements of operations. In May 2016, the Company completed the sale of BioZone, which resulted in a reduction of various components of property and equipment of $2.0 million. See additional information in Note 6. As disclosed further in Note 4, the Company executed a restructuring plan in August 2015 and wrote-off certain long-lived assets, primarily leasehold improvements, related to the abandonment of certain leased facilities. The write-off of long-lived assets of $26,000 is included as a component of restructuring and other charges in the accompanying condensed consolidated statements of operations for the six months ended June 30, 2016. There were no such write-offs for the six months ended June 30, 2015. Intangible Assets Intangible assets consist of the following (in thousands) and included the BioZone asset acquisition and MusclePharm’s apparel rights reacquired from Worldwide Apparel as of December 31, 2015. BioZone was sold during the three months ended June 30, 2016. As of June 30, 2016 Gross Value Accumulated Net Remaining Weighted- Amortized Intangible Assets Brand $ 2,244 $ (446 ) $ 1,798 5.6 Total intangible assets $ 2,244 $ (446 ) $ 1,798 As of December 31, 2015 Gross Value Accumulated Net Weighted- Amortized Intangible Assets Customer relationships $ 3,130 $ (417 ) $ 2,713 15.0 Non-compete agreements 69 (69 ) — — Patents 2,158 (540 ) 1,618 8.0 Trademarks 933 (133 ) 800 6.7 Brand 4,020 (522 ) 3,498 10.5 Domain name 54 (31 ) 23 5.0 Total intangible assets $ 10,364 $ (1,712 ) $ 8,652 Intangible assets amortization expense was $0.2 million and $0.3 million for the three months ended June 30, 2016 and 2015, respectively, and $0.4 million and $0.5 million for the six months ended June 30, 2016 and 2015, respectively, which is included in the selling, general, and administrative expense in the accompanying condensed consolidated statements of operations. Additionally, $1.2 million of trademarks with a net carrying value of $0.8 million related to the Arnold Schwarzenegger product line were considered impaired, and included as a component of the Impairment of assets in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2016, see additional information in Note 14. As of June 30, 2016, the estimated future amortization expense of intangible assets is as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 160 2017 321 2018 321 2019 321 2020 321 2021 321 Thereafter 33 Total amortization expense $ 1,798

Other Expense, net

Other Expense, net	6 Months Ended
	Jun. 30, 2016
Other Income and Expenses [Abstract]
Other Expense, net	Note 8. Other Expense, net During the three and six months ended June 30, 2016 and 2015, other expense, net consists of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Other expense, net: Interest expense $ (205 ) $ (133 ) $ (370 ) $ (258 ) Interest expense, factored accounts receivable (273 ) — (627 ) — Foreign currency transaction gain (loss) 91 (197 ) 194 (261 ) Other (205 ) (18 ) (501 ) (12 ) Total other expense, net $ (592 ) $ (348 ) $ (1,304 ) $ (531 )

Debt

Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt	Note 9. Debt As of June 30, 2016 and December 31, 2015, the Company’s debt consisted of the following (in thousands): June 30, December 31, Revolving line of credit $ — $ 3,000 Term loan — 2,949 Convertible note – with a related party, net of discount 5,976 5,952 Obligations under secured borrowing arrangement 7,361 — Other 11 21 Total debt 13,348 11,922 Less: current portion (13,348 ) (5,970 ) Long term debt $ — $ 5,952 In September 2014, the Company entered into a line of credit facility with ANB Bank for up to $8.0 million of borrowings. The line of credit originally matured in September 2017, and accrued interest at the prime rate plus 2%. The line of credit was secured by inventory, accounts receivable, intangible assets and equipment. As of December 31, 2015, the outstanding borrowings under the line of credit were $3.0 million. The Company was not in compliance with certain financial covenants under the line of credit as of December 31, 2015, which limited further borrowings. The Company repaid its outstanding principal and accrued interest under the line of credit in full in January 2016 in conjunction with the Company’s secured borrowing arrangement as described below. This line is no longer available to the Company. In February 2015, the Company entered into a $4.0 million term loan agreement with ANB Bank. The term loan carried a fixed interest rate of 5.25% per annum, was repayable in 36 equal monthly installments of principal and interest, and originally matured in February 2018. The term loan contained various events of default, including cross default provisions related to the line of credit, which could have required repayments of the term loan. The Company was not in compliance with certain financial covenants under the term loan as of December 31, 2015, and received various waivers from the lender during the year ended December 31, 2015. As of December 31, 2015, the outstanding borrowings under the term loan were $2.9 million. The Company repaid its outstanding principal and accrued interest under the term loan in full in January 2016 to retire the term loan in conjunction with the Company’s secured borrowing arrangement as described below. In October 2015, the Company entered into loan modification agreements with ANB Bank under the line of credit and term loan to: (i) change the maturity date of the loans to January 15, 2016, (ii) prohibit the loans to be declared in default prior to December 10, 2015, except for defaults resulting from failure to make timely payments, and (iii) delete certain financial covenants from the line of credit. In consideration for these modifications, Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, and a family member provided their individual guaranty for the remaining balance of the term loan and line of credit of $6.2 million. In consideration for executing his guaranty, the Company issued to Mr. Drexler 28,571 shares of the Company’s common stock with a grant date fair value of $80,000 (based upon the closing price of the Company’s common stock on the date of issuance). In December 2015, the Company entered into a convertible secured promissory note agreement with Mr. Drexler, pursuant to which he loaned the Company $6.0 million. Proceeds from the note were used to fund working capital requirements. The convertible note is secured by all assets and properties of the Company and its subsidiaries whether tangible or intangible. The convertible note carries an interest at 8% per annum, or 10% in the event of default. Both the principal and the interest under the convertible note are due in January 2017, unless converted earlier. The holder can convert the outstanding principal and accrued interest into shares of common stock (2,608,695 shares) for $2.30 per share at any time. The Company may prepay the convertible note at the aggregate principal amount therein plus accrued interest by giving the holder between 15 and 60 day-notice, depending upon the specific circumstances, provided that the holder may convert the note during the notice period. The Company recorded the convertible note of $6.0 million as a liability in the balance sheet and also recorded a beneficial conversion feature of $52,000 as a debt discount upon issuance of the convertible note, which is being amortized over the term of the convertible debt using the effective interest method. The beneficial conversion feature was calculated based on the difference between the fair value of common stock and the effective conversion price of the convertible note. As of June 30, 2016 and December 31, 2015, the convertible note had an outstanding principal balance of $6.0 million. In January 2016, the Company entered into a Purchase and Sale Agreement (the “Agreement”) with Prestige Capital Corporation (“Prestige”) pursuant to which the Company agreed to sell and assign and Prestige agreed to buy and accept, certain accounts receivable owed to the Company (“Accounts”). Under the terms of the Agreement, upon the receipt and acceptance of each assignment of Accounts, Prestige will pay the Company 80% of the net face amount of the assigned Accounts, up to a maximum total borrowings of $10.0 million subject to sufficient amounts of accounts receivable to secure the loan. The remaining 20% will be paid to the Company upon collection of the assigned Accounts, less any chargeback, disputes, or other amounts due to Prestige. Prestige’s purchase of the assigned Accounts from the Company will be at a discount fee which varies based on the number of days outstanding from the assignment of Accounts to collection of the assigned Accounts. In addition, the Company granted Prestige a continuing security interest in and lien upon all accounts receivable, inventory, fixed assets, general intangibles and other assets. The Agreement’s initial term of six months has been extended by the Company. Prestige may cancel the Agreement with 30-day notice. During the three and six months ended June 30, 2016, the Company sold to Prestige accounts with an aggregate face amount of approximately $20.4 million and $49.3 million, respectively. During the three and six months ended June 30, 2016, Prestige paid to the Company approximately $16.4 million and $39.5 million in cash, respectively. During the three and six months ended June 30, 2016, $13.8 million and $31.3 million was subsequently repaid to Prestige. The proceeds from the initial assignment to Prestige under this secured borrowing arrangement were primarily utilized to pay off the balance of the existing line of credit and term loan with ANB Bank. Other Other debt primarily consists of debt in default, which was immaterial, as of June 30, 2016 and December 31, 2015 and is included as a component of short-term debt. Debt in default is related to convertible debt issued during the year ended December 31, 2012 and prior where the convertible debt was never converted to common stock, nor was the principal repaid. The Company is in the process of contacting the remaining debt holder and negotiating settlement of the debt.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10. Commitments and Contingencies Operating Leases The Company leases office and warehouse facilities under operating leases, which expire at various dates through 2020. The amounts reflected in the table below are for the aggregate future minimum lease payments under non-cancelable facility operating leases. Under lease agreements that contain escalating rent provisions, lease expense is recorded on a straight-line basis over the lease term. Rent expense was $293,000 and $384,000 for the three months ended June 30, 2016 and 2015, respectively, and $639,000 and $767,000 for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, future minimum lease payments are as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 388 2017 564 2018 577 2019 416 2020 140 2021 — Thereafter — Total minimum lease payments $ 2,085 (1) The amounts in the table above exclude $0.5 million in operating lease liabilities resulting from the restructuring plan expensed through June 30, 2016 (see Note 4). Capital Leases In December 2014, the Company entered into a capital lease agreement providing for approximately $1.8 million in credit to lease up to 50 vehicles as part of a fleet lease program. As of June 30, 2016, the Company was leasing 11 vehicles under the capital lease and the original cost, net of accumulated depreciation, of leased assets was $362,000 and $91,000, respectively, which are included in property and equipment in the condensed consolidated balance sheets. As of December 31, 2015, the Company was leasing 21 vehicles under the capital lease and the original cost and accumulated depreciation of leased assets was $670,000 and $90,000, respectively, which are included in property and equipment in the condensed consolidated balance sheets. The Company also leases manufacturing and warehouse equipment under capital leases, which expire at various dates through February 2020. As of June 30, 2016 and December 31, 2015, short-term capital lease liabilities of $37,000 and $186,000, respectively are included as a component of current liabilities, and the long-term capital lease liabilities of $7,000 and $330,000, respectively are included as a component of long-term liabilities in the condensed consolidated balance sheets. As of June 30, 2016, the Company’s future minimum lease payments under capital lease agreements are as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 56 2017 101 2018 69 2019 30 2020 1 Total minimum lease payments 257 Less amounts representing interest (17 ) Present value of minimum lease payments $ 240 The Company entered into a product development and supply agreement with Flavor Producers, Inc. (“FPI”), the parent company of the buyer of BioZone, to develop certain products to be sold by the Company. If the product development effort is successful, the minimum purchase commitment under the product development and supply agreement with FPI is $3.0 million over the term of 12 months. Contingencies In the normal course of business or otherwise, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of June 30, 2016 and December 31, 2015, the Company was not involved in any material legal proceedings, with the exception of third-party manufacturer dispute and the lawsuit with a former executive, as described below. Third-Party Manufacturer Dispute The Company is engaged in a dispute with Capstone concerning amounts allegedly owed under the Manufacturing Agreement. Capstone claims that it is owed approximately $22.0 million of outstanding accounts payable, of which $20.7 million was included in the Company’s accounts payable balance as of June 30, 2016. The companies are working to reconcile the $1.3 million variance which relates to invoices not received by the Company as well as questions about shipping and receiving documentation to support potentially open invoices as claimed by Capstone. The Company claims that Capstone owes the Company at least $13.5 million in losses caused by, among other things, Capstone’s failure to timely manufacture and supply the Company’s products. In February 2016, Capstone requested a mediation with the American Arbitration Association which was held in May 2016 in New York. The mediation did not result in any resolution to this matter. As of June 30, 2016, Capstone has filed suit against the Company and the Company has filed countersuit in response. The Company believes that Capstone’s complaint is without merit. The Company alleges that Capstone, and its parent company INI, collaborated to intentionally harm its business and was, and still is, unable to fill orders placed by the Company. See additional information in Note 5. Supplier Complaint In January 2016, ThermoLife International LLC (“ThermoLife”), a supplier of nitrates to MusclePharm, filed a complaint against the Company in Arizona state court. In its complaint, ThermoLife alleges that the Company failed to meet minimum purchase requirements contained in the parties’ supply agreement. In March 2016, the Company filed an answer to ThermoLife’s complaint, denying the allegations contained in the complaint, and filed a counterclaim alleging that ThermoLife breached its express warranty to MusclePharm because ThermoLife’s products were defective and could not be incorporated into the Company’s products. Therefore, the Company believes that ThermoLife’s complaint is without merit. Former Executive Lawsuit In December 2015, the Company accepted notice by Mr. Richard Estalella (“Estalella”) to terminate his employment as the Company’s President. Although Estalella sought to terminate his employment with the Company for “Good Reason,” as defined in Estalella’s employment agreement with the Company (the “Employment Agreement”), the Company advised Estalella that it deemed his resignation to be without Good Reason. In February 2016, Estalella filed a complaint in Colorado state court against the Company and Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, alleging, among other things, that the Company breached the Employment Agreement, and seeking certain equitable relief and unspecified damages. The Company believes Estalella’s claims are without merit. During the quarter ended June 30, 2016, Estalella was not reelected to the Company’s Board of Directors and is no longer a member of the Board. As of the date of this report, the Company has evaluated the potential outcome of this lawsuit and recorded the liability consistent with its policy. Shareholder Derivative Complaint In October 2015, Brian D. Gartner, derivatively and on behalf of MusclePharm Corporation, filed a verified shareholder derivative complaint in the 8th District Court, State of Nevada, Clark County (No. A-15-726810-B) alleging, among other things, breaches of fiduciary duty as members of the Board of Directors and/or executive officers of the Company against Brad Pyatt, Lawrence S. Meer, Donald W. Prosser, Richard Estalella, Jeremy R. Deluca, Michael J. Doron, Cory Gregory, L. Gary Davis, James J. Greenwell, John H. Bluher and Daniel J. McClory. Mr. Gartner alleges a series of accounting and disclosure failures resulted in the filing of materially false and misleading filings with the SEC from 2010 through July 2014, resulting in settlement with the SEC requiring payment of $700,000 of civil penalties. Mr. Gartner seeks various remedies, including interpretation of bylaws provisions, permanent injunctive relief, damages against the defendants for breaches of their fiduciary duty, corporate governance changes to ensure the Company maintains proper internal controls and SEC reporting procedures, as well as costs and reasonable attorneys’ fees, accountants’ and experts’ fees, costs and expenses. The individual defendants have sought removal of the action to federal court and a scheduling stipulation is pending. The case continues in Nevada District Court with the most recent action being the filing of affidavits of service by the plaintiff. Insurance Carrier Lawsuit In February 2015, the Company filed a complaint in the District Court, City and County of Denver, Colorado against Liberty Insurance Underwriters, Inc. (“Liberty”) claiming wrongful and unreasonable denial of coverage for the cost and expenses that the Company incurred in connection with the SEC investigation and related matters under the Company’s Directors and Officers insurance policies. In August 2016, this case was dismissed. Sponsorship and Endorsement Contract Liabilities The Company has various non-cancelable endorsement and sponsorship agreements with terms expiring through 2022. The total value of future contractual payments as of June 30, 2016 are as follows (in thousands): Year Ending December 31, Remainder of 2016 2017 2018 2019 2020 Thereafter Total Outstanding Payments Endorsement $ 128 $ 80 $ — $ — $ — $ — $ 208 Sponsorship 2,345 2,294 2,404 985 — — 8,028 Total future payments $ 2,473 $ 2,374 $ 2,404 $ 985 $ — — $ 8,236

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity	Note 11. Stockholders’ Equity Common Stock For the six months ended June 30, 2016, the Company had the following transactions related to its common stock including restricted stock awards (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Shares issued to employees, executives and directors 179,140 $ 1,142 $ 1.89-2.95 Shares issued related to sale of subsidiary 200,000 640 $ 3.20 Cancellation of executive restricted stock (333,000 ) — $ 12.50 Total 46,140 $ 1,782 $ 1.89-12.50 For the six months ended June 30, 2015, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction T ype Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 244,589 $ 6,211 $ 3.48-8.60 Stock issued in conjunction with product line expansion 150,000 1,198 $ 7.99 Stock issued in conjunction with MusclePharm apparel rights acquisition 170,000 1,394 $ 8.20 Stock issued in conjunction with financing agreement 50,000 325 $ 6.49 Stock issued in conjunction with consulting/endorsement agreement 50,000 292 $ 5.85 Total 664,589 $ 9,420 $ 3.48-8.60 The fair value of all stock issuances above is based upon the quoted closing trading price on the date of issuance. Common stock outstanding as of June 30, 2016 and December 31, 2015 has been adjusted to include shares legally outstanding even if subject to future vesting. Treasury Stock For the three and six months ended June 30, 2016 and 2015, the Company did not repurchase any shares of its common stock and held 875,621 shares in treasury as of June 30, 2016 and December 31, 2015. As of December 31, 2015, 860,900 of the Company’s shares held in treasury were subject to a pledge with a lender in connection with a term loan. As of June 30, 2016, the pledge on these shares was cancelled as the term loan was paid off in January 2016.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation The Company’s stock-based compensation for the six months ended June 30, 2016 consist primarily of restricted stock awards. The activity of restricted stock awards granted to employees, executives and board members was as follows: Unvested Restricted Stock Awards Number of Shares Weighted- Average Grant Date Fair Value Unvested balance – December 31, 2015 1,025,999 $ 12.34 Granted 179,140 2.17 Vested (609,139 ) 11.55 Cancelled (260,000 ) 13.00 Unvested balance – June 30, 2016 336,000 7.69 The total fair value of restricted stock awards granted to employees and board members was $100,000 and $825,000 for the three months ended June 30, 2016 and 2015, respectively, and $389,000 and $900,000 for the six months ended June 30, 2016 and 2015. As of June 30, 2016 and December 31, 2015, the total unrecognized expense for unvested restricted stock awards, net of expected forfeitures, was $1.5 million and $8.5 million, respectively, which is expected to be amortized over a weighted-average period of 2.2 years and 3.0 years, respectively. Accelerated Vesting of Restricted Stock Awards Related to Brad Pyatt’s, Former Chief Executive Officer, Termination of Employment Agreement In March 2016, Brad Pyatt, the Company’s former Chief Executive Officer, terminated his employment with the Company. Pursuant to the terms of the separation agreement with the Company, in exchange for a release of claims, the Company agreed to pay severance in the amount of $1.1 million, payable over a 12-month period, a lump sum of $250,000 payable in March 2017 and reimbursement of COBRA premiums. In addition, the remaining unvested restricted stock awards held by Brad Pyatt of 500,000 shares vested in full upon his termination in accordance with the original grant terms. In connection with the accelerated vesting of these restricted stock awards, the Company recognized stock compensation expense of $3.9 million, which is included in the salaries and benefits expense in the accompanying consolidated statement of operations for the six months ended June 30, 2016. Stock Options In February 2016, the Company issued options under the 2015 Equity Incentive Plan to purchase 137,362 shares of its common stock to Mr. Drexler, the Company’s Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, and 54,945 to Michael Doron, the Lead Director of the Board of Directors. These stock options have a contractual term of 10 years and a grant date fair value of $294,000, which is amortized on a straight-line basis over the vesting period of two years. The Company determined the fair value of the stock options using the Black-Scholes model. For the three and six months ended June 30, 2016, the Company recorded stock compensation expense of $41,000 and $55,000, respectively. There were no options granted in the six months ended June 30, 2015. Restricted Stock Awards Related to Energy Drink Agreement In January 2015, the Company entered into an energy drink agreement with Langer Juice and Creative Flavor Concepts to expand into a new product line. In connection with the agreement, the Company issued a total of 150,000 shares of its restricted common stock with trade restrictions for a period of three years. The restricted stock awards issued had a grant date fair value of approximately $1.2 million, which was initially included as a component of prepaid stock compensation and additional paid-in capital in the condensed consolidated balance sheets upon issuance. The prepaid stock compensation was originally amortized over the performance period of ten years. In connection with the restructuring plan disclosed further in Note 4, the Company discontinued this product and wrote off the unamortized prepaid stock compensation of $1.1 million in August 2015. Agreements with Worldwide Apparel, LLC – MusclePharm Apparel Rights In February 2015, the Company entered into an agreement with Worldwide Apparel, LLC (“Worldwide”) to terminate Worldwide’s right to use MusclePharm’s brand images in apparel effective March 28, 2015. The brand rights were originally licensed in May 2011, and amended in March 2014 prior to the termination. The consideration related to the acquisition of the MusclePharm Apparel from Worldwide consists of a cash consideration of $850,000 and 170,000 shares of MusclePharm common stock with an aggregated fair value of $1.4 million. The total cost of the MusclePharm apparel acquisition of $2.2 million was included in the caption brand within intangible assets, net, in the accompanying consolidated balance sheet, and was subject to amortization over a period of seven years. Restricted Stock Awards Issued Related to Attempted Financing Agreement In May 2015, the Company negotiated the termination of an attempted financing agreement with a lending institution and issued 50,000 shares of its common stock. The fair value of the common stock was $325,000 based upon the closing price of the Company’s common stock on the date of issuance, and was recorded as selling, general and administrative expense. Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement In May 2015, the Company entered into consulting and endorsement agreements with William Phillips. In connection with the endorsement agreements, the Company agreed to issue a total of 50,000 shares of its restricted common stock. The restricted common stock issued had a grant date fair value of $292,000, which was included as a component of prepaid stock compensation and additional paid-in capital in the condensed consolidated balance sheets upon issuance. The prepaid stock compensation was originally amortized over the performance period of three years. In connection with the restructuring disclosed in Note 4, the Company terminated the consulting and endorsement agreements with William Phillips and wrote-off the unamortized prepaid stock compensation of $268,000 in August 2015. In connection with the consulting agreement, the Company also agreed to issue restricted shares worth $25,000 (based upon the weighted average stock price during the 15-day-period prior to issuance) within 10 days after each subsequent three-month period term. In July 2015, the Company issued 5,189 shares of its common stock to William Phillips. The fair value of the common stock was $28,000 based upon the closing price of the Company’s common stock on the date of issuance, and was recorded as advertising and promotion expense. No additional common stock will be issued to William Phillips under this agreement. Restricted Stock Awards Issued to Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, Related to Loan Modification In October 2015, the Company entered into loan modification agreements with the banking institution under its line of credit and term loan to: (i) change the maturity date of the loans to January 15, 2016, (ii) prohibit the loans to be declared in default prior to December 10, 2015, except for defaults resulting from failure to make timely payments, and (iii) delete certain financial covenants from the line of credit. In consideration for these modifications, Ryan Drexler, Interim Chief Executive Officer, Interim President and Chairman of the Board of Directors, and a family member, provided their individual guaranty for the remaining balance of the loans ($6.2 million). In consideration for executing his guaranty, the Company issued to Mr. Drexler 28,571 shares of common stock with a grant date fair value of $80,000 (based upon the closing price of the Company’s common stock on the date of issuance). Restricted Stock Awards to Non-Employees In July 2014, in connection with an endorsement agreement, the Company issued 446,853 shares of its restricted common stock to ETW with an aggregate market value of $5.0 million, as further described in Note 14. In September 2014, the Company entered into a consulting agreement with a third-party service provider and issued 30,000 shares of its restricted common stock with an aggregate market value of $402,000. These restricted stock awards granted to non-employees were initially included as a component of prepaid stock compensation and additional paid-in capital in the consolidated balance sheet upon issuance. The prepaid stock compensation was originally amortized over the performance period. In connection with the restructuring plan disclosed further in Note 4, the Company wrote-off the unamortized prepaid stock compensation related to these restricted stock awards to non-employees of $3.8 million in August 2015.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Net Loss per Share	Note 13. Net Loss per Share Basic net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock outstanding during each period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company uses the treasury stock method to determine whether there is a dilutive effect of outstanding option and warrant contracts. The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net loss $ (4,196 ) $ (7,025 ) $ (10,801 ) $ (14,504 ) Weighted-average common shares used in computing net loss per share, basic and diluted 13,874,209 13,647,267 13,855,754 13,491,433 Net loss per share, basic and diluted $ (0.30 ) $ (0.51 ) $ (0.78 ) $ (1.08 ) The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: As of June 30, 2016 2015 Stock options (exercise price - $1.89 per share) 192,307 — Warrants (exercise price - $11.90 per share) 100,000 — Unvested restricted stock 336,000 2,309,193 Convertible note (exercise price - $2.30 per share) 2,608,695 — Total common stock equivalents 3,237,002 2,309,193

Endorsement Agreements

Endorsement Agreements	6 Months Ended
	Jun. 30, 2016
Text Block [Abstract]
Endorsement Agreements	Note 14. Endorsement Agreements Arnold Schwarzenegger In July 2013, the Company entered into an Endorsement Licensing and Co-Branding Agreement by and among the Company, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Under the terms of the agreement, Mr. Schwarzenegger was co-developing a special Arnold Schwarzenegger product line being co-marketed under Mr. Schwarzenegger’s name and likeness. In connection with this agreement, the Company also issued to Marine MP, LLC fully vested restricted shares of common stock with an aggregate market value of $8.5 million. The shares are being amortized over the original three-year term of the agreement. In May 2016, the Company received written notice to terminate the Endorsement Licensing and Co-Branding Agreement effective immediately. As a result, $1.9 million of intangible assets, prepaid assets and inventory related to the Arnold Schwarzenegger product line was written off as an impairment expense. The agreement to terminate the product line stipulates that no further use of his likeness or sales of the inventory were allowed and we, therefore, disposed of all remaining product in inventory. ETW In July 2014, the Company entered into an Endorsement Agreement with ETW. Under the terms of the agreement, Tiger Woods agreed to endorse certain of the Company’s products and use a golf bag during all professional golf play that prominently displayed the MusclePharm name and logo. In conjunction with this agreement, the Company issued 446,853 shares of the Company’s restricted common stock to ETW, with an aggregate market value of $5.0 million. The shares were amortized over the original four-year term of the agreement. The current and non-current portions of the unamortized stock compensation were initially included as a component of prepaid stock compensation in the condensed consolidated balance sheets. The amount of unamortized stock compensation expense of $3.5 million related to this agreement was written off in connection with the restructuring plan disclosed further in Note 4. In May 2016, the Company entered into a settlement agreement with ETW, which eliminates all costs and terminates all future commitments under the Endorsement Agreement. Pursuant to the settlement agreement, the Company agreed to pay to ETW, $2.2 million to terminate the parties’ obligations under Endorsement Agreement and to resolve all disputes between the parties. As a result, the Company adjusted its restructuring accrual balance from $7.0 million to $2.2 million according to the settlement agreement and recorded an expense credit of $4.8 million during the three and six months ended June 30, 2016. Johnny Manziel In July 2014, the Company entered into an Endorsement Agreement for the services of Johnny Manziel. As part of this agreement, the Company issued a warrant to purchase 100,000 shares of its common stock at an exercise price of $11.90 per share. The warrants vest monthly over a period of 24 months beginning August 15, 2014, and have a five-year contractual term. The Company recognized stock-based compensation expense of $3,000 and $17,000 for the three months ended June 30, 2016 and 2015, respectively, and $6,000 and $50,000 for the six months ended June 30, 2016 and 2015, respectively, related to these warrants, which is included as a component of advertising and promotion expense in the accompanying condensed consolidated statements of operations. The Company used the Black-Scholes model to determine the estimated fair value of the warrants, with the following assumptions: contractual life of five years, risk free interest rate of 1.7%, dividend yield of 0%, and expected volatility of 55%. In connection with the restructuring disclosed in Note 4, the Company notified Johnny Manziel of its intention to terminate the endorsement agreement; however, Johnny Manziel disputes the termination notice. As of June 30, 2016, 95,834 shares were vested under the warrant.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The Company recorded an income tax provision of $7,000 and $21,000 for the three months ended June 30, 2016 and 2015, respectively, and $138,000 and $33,000 for the six months ended June 30, 2016 and 2015, related to foreign income taxes and federal and state minimum taxes. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due. Deferred taxes relate to differences between the basis of assets and liabilities for financial and income tax reporting which will be either taxable or deductible when the assets or liabilities are recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has established a full valuation allowance as it is more likely than not that the tax benefits will not be realized as of June 30, 2016.

Geographical Information

Geographical Information	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Geographical Information	Note 16. Geographical Information The Company’s chief operating decision maker reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. As such, the Company currently has a single reporting segment and operating unit structure. In addition, most of the Company’s revenue and substantially all long-lived assets are attributable to operations in the U.S. for all the periods presented. Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Revenue, net: United States $ 23,519 $ 36,270 $ 53,211 $ 67,858 International 9,348 14,206 22,568 23,940 Total revenue, net $ 32,867 $ 50,476 $ 75,779 $ 91,798

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events GAAP requires an entity to disclose events that occur after the balance sheet date but before financial statements are issued or are available to be issued (“subsequent events”) as well as the date through which an entity has evaluated subsequent events. There are two types of subsequent events. The first type consists of events or transactions that provide additional evidence about conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements, (“recognized subsequent events”). The second type consists of events that provide evidence about conditions that did not exist at the date of the balance sheet but arose subsequent to that date (“non-recognized subsequent events”). No significant recognized or non-recognized subsequent events were noted through the date of this filing. However, in conjunction with the restructuring plans, the plan the executive management team has decided to close the accounting and administration office in Denver and is in the process of negotiating a sublease for the distribution center in Pittsburg California. These closures will take place during the third quarter of 2016.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The condensed consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these statements do not include all of the information and notes required by GAAP for complete financial statements. In our opinion, the unaudited interim condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of June 30, 2016, our results of operations for the three and six months ended June 30, 2016 and 2015, and our cash flows for the six months ended June 30, 2016 and 2015. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 17, 2016.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and tax assets, the assessment of useful lives, recoverability and valuation of long-lived assets, likelihood and range of possible losses on contingencies, restructuring liabilities, valuations of equity securities and intangible assets, fair value of derivatives, warrants and options, among others. Actual results could differ from those estimates.
Stock-Based Compensation	Stock-Based Compensation The Company estimates the fair value of employee stock options on the date of grant using the Black-Scholes option-pricing model. The determination of the fair value of each stock award using this option-pricing model is affected by the Company’s assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards and the expected term of the awards based on an analysis of the actual and projected employee stock option exercise behaviors and the contractual term of the awards. The Company recognizes stock-based compensation expense over the requisite service period, which is generally consistent with the vesting of the awards, based on the estimated fair value of all stock-based payments issued to employees and directors that are expected to vest.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition- Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Schedule of Provision of Restructuring and Accrued Restructuring Charges	The following table illustrates the provision of the restructuring charges and the accrued restructuring charges balance as of June 30, 2016 and December 31, 2015 (in thousands): Employee Severance Costs Contract Termination Costs Purchase Commitment of Discontinued Inventories Not Yet Received Abandoned Lease Facilities Total Balance as of December 31, 2014 $ — $ — $ — $ — $ — Expensed 1,353 6,979 350 467 9,149 Cash payments (845 ) (949 ) — (56 ) (1,850 ) Reclassification from accounts payable to restructuring charges — 2,120 — — 2,120 Balance as of December 31, 2015 508 8,150 350 411 9,419 Expensed 410 — — (51 ) 359 Benefit from settlement of Endorsement Agreement with ETW — (4,750 ) — — (4,750 ) Cash payments (896 ) (2,366 ) (175 ) (82 ) (3,519 ) Balance as of June 30, 2016 $ 22 $ 1,034 $ 175 $ 278 $ 1,509
Schedule of Future Payments Under The Restructuring Plan	The total future payments under the restructuring plan as of June 30, 2016 are as follows (in thousands): Year Ending December 31, Outstanding Payments Remainder of 2016 2017 2018 2019 2020 2021 Total Contract termination costs $ 1,034 $ — $ — $ — $ — $ — $ 1,034 Purchase commitment of discontinued inventories not yet received 175 — — — — — 175 Employee severance costs 22 — — — — — 22 Abandoned leased facilities 36 75 77 79 11 — 278 Total future payments $ 1,267 $ 75 $ 77 $ 79 $ 11 $ — $ 1,509

Sale of BioZone (Tables)

Sale of BioZone (Tables)	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Summary of Components of Loss from Sale of Bio Zone	The following table summarizes the components of the loss from the sale of BioZone (in thousands): Cash proceeds from sale $ 5,942 Consideration for common stock transferred 50 Prepaid inventory 2,000 Fair market value of the common stock transferred (640 ) Assets sold: Accounts receivable, net (923 ) Inventory, net (1,761 ) Fixed assets, net (2,003 ) Intangible assets, net (5,657 ) All other assets (41 ) Liabilities transferred 1,197 Transaction and other costs (279 ) Loss on sale of subsidiary $ (2,115 )

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory consisted of the following as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, Raw materials $ — $ 1,385 Work-in-process — 22 Finished goods 6,941 11,142 Inventory $ 6,941 $ 12,549
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following as of June 30, 2016 and December 31, 2015 (in thousands): June 30, December 31, Furniture, fixtures and equipment $ 3,803 $ 3,621 Leasehold improvements 2,519 3,227 Manufacturing and lab equipment 13 1,659 Vehicles 653 1,146 Displays 486 483 Website 458 463 Construction in process 41 54 Property and equipment, gross 7,973 10,653 Less: accumulated depreciation and amortization (4,087 ) (3,960 ) Property and equipment, net $ 3,886 $ 6,693
Schedule of Intangible Assets	Intangible assets consist of the following (in thousands) and included the BioZone asset acquisition and MusclePharm’s apparel rights reacquired from Worldwide Apparel as of December 31, 2015. BioZone was sold during the three months ended June 30, 2016. As of June 30, 2016 Gross Value Accumulated Net Remaining Weighted- Amortized Intangible Assets Brand $ 2,244 $ (446 ) $ 1,798 5.6 Total intangible assets $ 2,244 $ (446 ) $ 1,798 As of December 31, 2015 Gross Value Accumulated Net Weighted- Amortized Intangible Assets Customer relationships $ 3,130 $ (417 ) $ 2,713 15.0 Non-compete agreements 69 (69 ) — — Patents 2,158 (540 ) 1,618 8.0 Trademarks 933 (133 ) 800 6.7 Brand 4,020 (522 ) 3,498 10.5 Domain name 54 (31 ) 23 5.0 Total intangible assets $ 10,364 $ (1,712 ) $ 8,652
Schedule of Estimated Future Amortization Expense of Intangible Assets	As of June 30, 2016, the estimated future amortization expense of intangible assets is as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 160 2017 321 2018 321 2019 321 2020 321 2021 321 Thereafter 33 Total amortization expense $ 1,798

Other Expense, net (Tables)

Other Expense, net (Tables)	6 Months Ended
	Jun. 30, 2016
Other Income and Expenses [Abstract]
Other Expense, net	During the three and six months ended June 30, 2016 and 2015, other expense, net consists of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Other expense, net: Interest expense $ (205 ) $ (133 ) $ (370 ) $ (258 ) Interest expense, factored accounts receivable (273 ) — (627 ) — Foreign currency transaction gain (loss) 91 (197 ) 194 (261 ) Other (205 ) (18 ) (501 ) (12 ) Total other expense, net $ (592 ) $ (348 ) $ (1,304 ) $ (531 )

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long Term Debt	As of June 30, 2016 and December 31, 2015, the Company’s debt consisted of the following (in thousands): June 30, December 31, Revolving line of credit $ — $ 3,000 Term loan — 2,949 Convertible note – with a related party, net of discount 5,976 5,952 Obligations under secured borrowing arrangement 7,361 — Other 11 21 Total debt 13,348 11,922 Less: current portion (13,348 ) (5,970 ) Long term debt $ — $ 5,952

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	As of June 30, 2016, future minimum lease payments are as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 388 2017 564 2018 577 2019 416 2020 140 2021 — Thereafter — Total minimum lease payments $ 2,085 (1) The amounts in the table above exclude $0.5 million in operating lease liabilities resulting from the restructuring plan expensed through June 30, 2016 (see Note 9).
Schedule of Future Minimum Lease Payments for Capital Leases	As of June 30, 2016, the Company’s future minimum lease payments under capital lease agreements are as follows (in thousands): Year Ending December 31, The remainder of 2016 $ 56 2017 101 2018 69 2019 30 2020 1 Total minimum lease payments 257 Less amounts representing interest (17 ) Present value of minimum lease payments $ 240
Contractual Obligation, Fiscal Year Maturity Schedule	The total value of future contractual payments as of June 30, 2016 are as follows (in thousands): Year Ending December 31, Remainder of 2016 2017 2018 2019 2020 Thereafter Total Outstanding Payments Endorsement $ 128 $ 80 $ — $ — $ — $ — $ 208 Sponsorship 2,345 2,294 2,404 985 — — 8,028 Total future payments $ 2,473 $ 2,374 $ 2,404 $ 985 $ — — $ 8,236

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Schedule of Stockholders Equity	For the six months ended June 30, 2016, the Company had the following transactions related to its common stock including restricted stock awards (in thousands, except share and per share data): Transaction Type Quantity (Shares) Valuation ($) Range of Value per Share Shares issued to employees, executives and directors 179,140 $ 1,142 $ 1.89-2.95 Shares issued related to sale of subsidiary 200,000 640 $ 3.20 Cancellation of executive restricted stock (333,000 ) — $ 12.50 Total 46,140 $ 1,782 $ 1.89-12.50 For the six months ended June 30, 2015, the Company issued common stock including restricted stock awards, as follows (in thousands, except share and per share data): Transaction T ype Quantity (Shares) Valuation ($) Range of Value per Share Stock issued to employees, executives and directors 244,589 $ 6,211 $ 3.48-8.60 Stock issued in conjunction with product line expansion 150,000 1,198 $ 7.99 Stock issued in conjunction with MusclePharm apparel rights acquisition 170,000 1,394 $ 8.20 Stock issued in conjunction with financing agreement 50,000 325 $ 6.49 Stock issued in conjunction with consulting/endorsement agreement 50,000 292 $ 5.85 Total 664,589 $ 9,420 $ 3.48-8.60

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Restricted Stock Units Activity	The activity of restricted stock awards granted to employees, executives and board members was as follows: Unvested Restricted Stock Awards Number of Shares Weighted- Average Grant Date Fair Value Unvested balance – December 31, 2015 1,025,999 $ 12.34 Granted 179,140 2.17 Vested (609,139 ) 11.55 Cancelled (260,000 ) 13.00 Unvested balance – June 30, 2016 336,000 7.69

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net loss $ (4,196 ) $ (7,025 ) $ (10,801 ) $ (14,504 ) Weighted-average common shares used in computing net loss per share, basic and diluted 13,874,209 13,647,267 13,855,754 13,491,433 Net loss per share, basic and diluted $ (0.30 ) $ (0.51 ) $ (0.78 ) $ (1.08 )
Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: As of June 30, 2016 2015 Stock options (exercise price - $1.89 per share) 192,307 — Warrants (exercise price - $11.90 per share) 100,000 — Unvested restricted stock 336,000 2,309,193 Convertible note (exercise price - $2.30 per share) 2,608,695 — Total common stock equivalents 3,237,002 2,309,193

Geographical Information (Table

Geographical Information (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Revenue, Net by Geographic Area	Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Revenue, net: United States $ 23,519 $ 36,270 $ 53,211 $ 67,858 International 9,348 14,206 22,568 23,940 Total revenue, net $ 32,867 $ 50,476 $ 75,779 $ 91,798

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Feb. 28, 2015	Dec. 31, 2014	Sep. 30, 2014
Schedule Of Description Of Business [Line Items]
Accumulated deficit	$ (158,318,000)	$ (147,517,000)
Line of Credit Facility, Maximum Borrowing Capacity	10,000,000
Principal amount of promissory note				$ 4,000,000
Proceed from issuance of convertible note		6,000,000
Cash	13,052,000	7,081,000	$ 4,170,000		$ 1,020,000
Working capital deficit	20,500,000
Proceeds from secured borrowing arrangement	49,300,000
Payments on secured borrowing arrangement	30,791,000
Total liabilities	$ 65,630,000	$ 73,849,000
ANB Bank [Member]
Schedule Of Description Of Business [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 8,000,000
Principal amount of promissory note				$ 4,000,000

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges	$ 4,800,000		$ 4,200,000		$ 21,200,000
Restructuring charges	500,000	$ 0	2,169,000	$ 0
Recovery of restructuring and other charges	4,800,000		4,800,000
Release of restructuring accrual	7,000,000		7,000,000
Restructuring charges to be paid in cash	1,509,000		1,509,000		9,419,000
ETW Corp Claims [Member]
Restructuring Cost and Reserve [Line Items]
Release of restructuring accrual related to settlement agreement	2,200,000		2,200,000
Purchase Commitment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	200,000		200,000
Cost of Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges	500,000		2,200,000		3,000,000
Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges					18,300,000
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			410,000
Stock-based compensation of terminated employees			100,000
Restructuring charges to be paid in cash	22,000		22,000		508,000
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges to be paid in cash	1,034,000		1,034,000		8,150,000
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Write-off of long-lived assets			100,000
Restructuring charges to be paid in cash	$ 278,000		$ 278,000		$ 411,000

Restructuring - Schedule of Pro

Restructuring - Schedule of Provision of Restructuring and Accrued Restructuring Charges (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Balance	$ 9,419
Expensed	359
Expensed		$ 9,149
Cash payments	(3,519)	(1,850)
Reclassification from accounts payable to restructuring charges		2,120
Balance	1,509	9,419
ETW Corp Claims [Member]
Restructuring Cost and Reserve [Line Items]
Benefit from settlement of Endorsement Agreement with ETW	(4,750)
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance	508
Expensed	410
Expensed		1,353
Cash payments	(896)	(845)
Balance	22	508
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Balance	8,150
Expensed		6,979
Cash payments	(2,366)	(949)
Reclassification from accounts payable to restructuring charges		2,120
Balance	1,034	8,150
Contract Termination Costs [Member] | ETW Corp Claims [Member]
Restructuring Cost and Reserve [Line Items]
Benefit from settlement of Endorsement Agreement with ETW	(4,750)
Purchase Commitment of Discontinued Inventories Not Yet Received [Member]
Restructuring Cost and Reserve [Line Items]
Balance	350
Expensed		350
Cash payments	(175)
Balance	175	350
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Balance	411
Expensed	(51)
Expensed		467
Cash payments	(82)	(56)
Balance	$ 278	$ 411

Restructuring - Schedule of Fut

Restructuring - Schedule of Future Payments Under The Restructuring Plan (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	$ 1,267
2,017	75
2,018	77
2,019	79
2,020	11
Total	1,509	$ 9,419
Contract Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	1,034
Total	1,034	8,150
Purchase Commitment of Discontinued Inventories Not Yet Received [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	175
Total	175	350
Employee Severance Costs [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	22
Total	22	508
Abandoned Leased Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Remainder of 2016	36
2,017	75
2,018	77
2,019	79
2,020	11
Total	$ 278	$ 411

Capstone Nutrition Agreements -

Capstone Nutrition Agreements - Additional Information (Detail) - USD ($)	Mar. 02, 2015	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Jul. 31, 2014
Business Acquisition [Line Items]
Contractual obligation		$ 8,236,000	$ 8,236,000
Common stock, par value		$ 0.001	$ 0.001	$ 0.001
Investment Warrants, Exercise Price					$ 11.90
Amortization period of expense			6 years 6 months
Impairment of assets		$ 4,313,000	$ 4,313,000
Accounts Payable [Member]
Business Acquisition [Line Items]
Loss contingency damage sought value			20,700,000
Loss contingency settlement amount			1,300,000
Capstone Claims [Member]
Business Acquisition [Line Items]
Loss contingency damage sought value			22,000,000
Loss contingency damage sought value by company			13,500,000
Capstone Claims [Member] | Accounts Payable [Member]
Business Acquisition [Line Items]
Loss contingency damage sought value			20,700,000
Loss contingency settlement amount			$ 1,300,000
Capstone [Member]
Business Acquisition [Line Items]
Contractual obligation	$ 2,500,000
Contribution toward Capstone Facility Build				$ 2,500,000
Impairment of assets		2,400,000
I N I [Member]
Business Acquisition [Line Items]
Percentage ownership interest agreed to purchase	19.90%
Investment Warrants, Exercise Price	$ 0.01
Aggregate enterprise value	$ 200,000,000
Option expiration date			Jun. 30, 2016
I N I [Member] | Common Class B [Member]
Business Acquisition [Line Items]
Common stock, par value	$ 0.001
Manufacturing Agreement [Member]
Business Acquisition [Line Items]
Impairment of assets		1,400,000
Long-Term Investments [Member]
Business Acquisition [Line Items]
Recorded value of Asset		$ 977,000	$ 977,000
Prepaid Expenses and Other Current Assets [Member]
Business Acquisition [Line Items]
Prepaid expenses and other assets				$ 1,500,000

Sale of BioZone - Additional In

Sale of BioZone - Additional Information (Detail) - USD ($)	May 31, 2016	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of subsidiary			$ (5,942,000)
Common stock, Shares transferred		14,710,301	14,710,301	14,664,161
Common stock, Value		$ 14,000	$ 14,000	$ 14,000
FPI [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase of products at the closing of the sale			3,000,000
Biozone [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of subsidiary	$ 9,800,000
Cash receivable subject to an earn-out based on the financial performance	1,500,000
Accounts payables pay down	$ 350,000
Common stock, Shares transferred	200,000
Common stock, Value	$ 640,000
Loss on sale of business	2,100,000	$ 500,000	$ 1,500,000
Proceeds from sale of subsidiary, Cash portion	5,900,000
Proceeds from sale of subsidiary, Credit portion	2,000,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 50,000
Purchase commitment, Term	3 years
Purchase of products at the closing of the sale	$ 3,000,000

Sale of BioZone - Summary of Co

Sale of BioZone - Summary of Components of Loss from Sale of Bio Zone (Detail) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)
Assets sold:
Loss on sale of subsidiary	$ (2,115)	$ (2,115)
Biozone [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale		5,942
Consideration for common stock transferred		50
Prepaid inventory	2,000	2,000
Fair market value of the common stock transferred	(640)	(640)
Assets sold:
Accounts receivable, net	(923)	(923)
Inventory, net	(1,761)	(1,761)
Fixed assets, net	(2,003)	(2,003)
Intangible assets, net	(5,657)	(5,657)
All other assets	(41)	(41)
Liabilities transferred	1,197	1,197
Transaction and other costs	$ (279)	(279)
Loss on sale of subsidiary		$ (2,115)

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory, Net [Abstract]
Raw materials		$ 1,385
Work-in-process		22
Finished goods	$ 6,941	11,142
Inventory	$ 6,941	$ 12,549

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Balance Sheet Components [Line Items]
Inventory write down related to corporate restructuring	$ 500,000	$ 0	$ 2,169,000	$ 0
Reduction of inventory			(1,359,000)	(6,219,000)
Depreciation and amortization expense	389,000	456,000	816,000	838,000
Write-off of long-lived assets related to the abandonment of certain lease facilities			26,000	0
Amortization of intangible assets	200,000	$ 300,000	416,000	$ 498,000
Finite-Lived Intangible Assets, Gross	2,244,000		2,244,000		$ 10,364,000
Finite-Lived intangible assets, net	1,798,000		1,798,000		8,652,000
Trademarks [Member]
Balance Sheet Components [Line Items]
Finite-Lived Intangible Assets, Gross					933,000
Finite-Lived intangible assets, net					$ 800,000
Arnold Schwarzenegger Product Line [Member]
Balance Sheet Components [Line Items]
Impairment of inventory	400,000		400,000
Arnold Schwarzenegger Product Line [Member] | Trademarks [Member]
Balance Sheet Components [Line Items]
Finite-Lived Intangible Assets, Gross	1,200,000		1,200,000
Finite-Lived intangible assets, net	800,000		800,000
Impairment charge	$ 800,000		800,000
Biozone [Member]
Balance Sheet Components [Line Items]
Reduction of inventory			1,800,000
Reduction of property and equipment			$ 2,000,000

Balance Sheet Components - Sc46

Balance Sheet Components - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,973	$ 10,653
Less: accumulated depreciation and amortization	(4,087)	(3,960)
Property and equipment, net	3,886	6,693
Furniture, Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,803	3,621
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,519	3,227
Manufacturing and Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	13	1,659
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	653	1,146
Displays [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	486	483
Website [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	458	463
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 41	$ 54

Balance Sheet Components - Sc47

Balance Sheet Components - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 2,244	$ 10,364
Finite-Lived Intangible Assets, Accumulated Amortization	(446)	(1,712)
Finite-Lived Intangible Assets, Net, Total	$ 1,798	8,652
Finite-Lived Intangible Asset, Remaining Useful Life	6 years 6 months
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 2,244	3,130
Finite-Lived Intangible Assets, Accumulated Amortization	(446)	(417)
Finite-Lived Intangible Assets, Net, Total	$ 1,798	$ 2,713
Finite-Lived Intangible Asset, Remaining Useful Life	5 years 7 months 6 days
Finite-Lived Intangible Asset, Useful Life		15 years
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		$ 69
Finite-Lived Intangible Assets, Accumulated Amortization		(69)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		2,158
Finite-Lived Intangible Assets, Accumulated Amortization		(540)
Finite-Lived Intangible Assets, Net, Total		$ 1,618
Finite-Lived Intangible Asset, Useful Life		8 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		$ 933
Finite-Lived Intangible Assets, Accumulated Amortization		(133)
Finite-Lived Intangible Assets, Net, Total		$ 800
Finite-Lived Intangible Asset, Useful Life		6 years 8 months 12 days
Brand [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		$ 4,020
Finite-Lived Intangible Assets, Accumulated Amortization		(522)
Finite-Lived Intangible Assets, Net, Total		$ 3,498
Finite-Lived Intangible Asset, Useful Life		10 years 6 months
Domain Name [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		$ 54
Finite-Lived Intangible Assets, Accumulated Amortization		(31)
Finite-Lived Intangible Assets, Net, Total		$ 23
Finite-Lived Intangible Asset, Useful Life		5 years

Balance Sheet Components - Sc48

Balance Sheet Components - Schedule of Estimated Future Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
The remainder of 2016	$ 160
2,017	321
2,018	321
2,019	321
2,020	321
2,021	321
Thereafter	33
Finite-Lived Intangible Assets, Net, Total	$ 1,798	$ 8,652

Other Expense, net - Other Expe

Other Expense, net - Other Expense, net (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other expense, net
Interest expense	$ (205)	$ (133)	$ (370)	$ (258)
Interest expense, factored accounts receivable	(273)		(627)
Foreign currency transaction gain (loss)	91	(197)	194	(261)
Other	(205)	(18)	(501)	(12)
Total other expense, net	$ (592)	$ (348)	$ (1,304)	$ (531)

Debt - Schedule of Long Term De

Debt - Schedule of Long Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Revolving line of credit		$ 3,000
Term loan		2,949
Convertible note with a related party, net of discount, current	$ 5,976
Convertible note with a related party, net of discount, long-term		5,952
Obligations under secured borrowing arrangement	7,361
Other	11	21
Total debt	13,348	11,922
Less: current portion	$ (13,348)	(5,970)
Long term debt		$ 5,952

Debt - Additional Information (

Debt - Additional Information (Detail)	1 Months Ended				3 Months Ended	6 Months Ended	12 Months Ended
	Jan. 31, 2016USD ($)	Oct. 31, 2015USD ($)shares	Feb. 28, 2015USD ($)Installments	Sep. 30, 2014USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2015USD ($)$ / sharesshares
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 10,000,000	$ 10,000,000
Line of credit							$ 3,000,000
Principal amount of promissory note			$ 4,000,000
Term loan and line of credit outstanding					13,348,000	13,348,000	11,922,000
Convertible note							5,952,000
Receipt from account receivable					13,800,000	31,300,000
Prestige Capital Corporation ("Prestige") [Member]
Debt Instrument [Line Items]
Percent of net face amount of assigned accounts receivable	80.00%
Percent of remaining face amount of assigned accounts receivable	20.00%
Sale of accounts					20,400,000	49,300,000
Cash received on account of sale of accounts					$ 16,400,000	$ 39,500,000
Prestige Capital Corporation ("Prestige") [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum amount receivable at any time	$ 10,000,000
ANB Bank [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 8,000,000
Line of Credit Facility, Expiration Date				Sep. 30, 2017
Debt Instrument, Basis Spread on Variable Rate				2.00%
Line of Credit Facility, Interest Rate Description						Prime rate plus 2%
Line of credit							$ 3,000,000
Principal amount of promissory note			$ 4,000,000
Interest on convertible note			5.25%				8.00%
Number of installments | Installments			36
Debt Instrument Maturity Date			Feb. 28, 2018
Term loan outstanding borrowings							$ 2,900,000
Debt Instrument, Convertible, Conversion Price | $ / shares							$ 2.30
Debt Instrument, Defaulted Interest Rate, Stated Percentage							10.00%
Debt instrument, maturity period							2017-01
Debt discount upon issuance of the convertible note							$ 52,000
ANB Bank [Member] | Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument Maturity Date		Jan. 15, 2016
Term loan and line of credit outstanding		$ 6,200,000
ANB Bank [Member] | Convertible Debt Securities [Member]
Debt Instrument [Line Items]
Common stock reserved for future conversion | shares							2,608,695
ANB Bank [Member] | Interim Chief Executive Officer, President and Chairman [Member] | Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Stock issued to chairman of the board of directors, shares | shares		28,571
Stock issued to chairman of the board of directors, value		$ 80,000
ANB Bank [Member] | Interim Chief Executive Officer, President and Chairman [Member] | Executive Chairman of Board of Directors Convertible Secured Promissory Note Agreement [Member]
Debt Instrument [Line Items]
Convertible note							$ 6,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Oct. 27, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)Vehicle	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)Vehicle	Dec. 31, 2014USD ($)Vehicle
Commitment And Contingencies [Line Items]
Operating Lease Expire Term				2,020
Operating Leases, Rent Expense, Net		$ 293,000	$ 384,000	$ 639,000	$ 767,000
Line of Credit Facility, Maximum Borrowing Capacity		10,000,000		$ 10,000,000
Capital Lease Expire Term				2020-02
Capital lease - short term		37,000		$ 37,000		$ 186,000
Capital Lease Obligations, Noncurrent		7,000		$ 7,000		330,000
Lease expiration term				2,022
2014 Lease Agreement [Member]
Commitment And Contingencies [Line Items]
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation		$ 91,000		$ 91,000		$ 90,000
Accounts Payable [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value				20,700,000
Loss contingency settlement amount				$ 1,300,000
Fleet Lease Program [Member]
Commitment And Contingencies [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity							$ 1.8
Number of vehicles acquired under capital lease | Vehicle				11		21
Fleet Lease Program [Member] | Maximum [Member]
Commitment And Contingencies [Line Items]
Number of vehicles for lease | Vehicle							50
Capstone Claims [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value				$ 22,000,000
Loss contingency damage sought value by company				13,500,000
Capstone Claims [Member] | Accounts Payable [Member]
Commitment And Contingencies [Line Items]
Loss contingency damage sought value				20,700,000
Loss contingency settlement amount				1,300,000
FPI [Member]
Commitment And Contingencies [Line Items]
Purchase of products at the closing of the sale				3,000,000
Vehicles [Member]
Commitment And Contingencies [Line Items]
Original cost of property acquired under capital lease				$ 362,000		$ 670,000
Securities And Exchange Commission [Member]
Commitment And Contingencies [Line Items]
Final settlement with the SEC	$ 700,000

Commitments and Contingencies53

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Year Ending December 31,
The remainder of 2016	$ 388
2,017	564
2,018	577
2,019	416
2,020	140
2,021	0
Thereafter	0
Total minimum lease payments	$ 2,085

Commitments and Contingencies54

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Parenthetical) (Detail) $ in Millions	Jun. 30, 2016USD ($)
Restructuring Charges [Member]
Leases Future Minimum Payments [Line Items]
Operating leases, liabilities	$ 0.5

Commitments and Contingencies55

Commitments and Contingencies - Schedule of Future Minimum Lease Payments for Capital Leases (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
The remainder of 2016	$ 56
2,017	101
2,018	69
2,019	30
2,020	1
Total minimum lease payments	257
Less amounts representing interest	(17)
Present value of minimum lease payments	$ 240

Commitments and Contingencies56

Commitments and Contingencies - Contractual Obligation, Fiscal Year Maturity Schedule (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2016	$ 2,473
2,017	2,374
2,018	2,404
2,019	985
Thereafter	0
Contractual Obligation, Total future payments	8,236
Endorsement [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2016	128
2,017	80
Thereafter	0
Contractual Obligation, Total future payments	208
Sponsorship [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Remainder of 2016	2,345
2,017	2,294
2,018	2,404
2,019	985
Thereafter	0
Contractual Obligation, Total future payments	$ 8,028

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stockholders Equity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Class of Stock [Line Items]
Shares issued related to sale of subsidiary, Valuation	$ 640
Cancellation of executive restricted stock, Valuation	$ 0
Common Stock [Member]
Class of Stock [Line Items]
Stock issued to employees, executives and directors, Quantity	179,140	244,589
Stock issued in conjunction with product line expansion, Quantity		150,000
Shares issued related to sale of subsidiary, Quantity	200,000
Cancellation of executive restricted stock, Quantity	(333,000)
Stock issued in conjunction with financing agreement, Quantity		50,000
Stock issued in conjunction with consulting/endorsement agreement, Quantity		50,000
Total, Quantity	46,140	664,589
Stock issued to employees, executives and directors, Valuation	$ 1,142	$ 6,211
Stock issued in conjunction with product line expansion, Valuation		1,198
Shares issued related to sale of subsidiary, Valuation	640
Cancellation of executive restricted stock, Valuation	0
Stock issued in conjunction with financing agreement, Valuation		325
Stock issued in conjunction with consulting/endorsement agreement, Valuation		292
Total, Valuation	$ 1,782	$ 9,420
Stock issued in conjunction with product line expansion, Range of Value per Share		$ 7.99
Shares issued related to sale of subsidiary, Range of Value per Share	$ 3.20
Stock issued in conjunction with financing agreement, Range of Value per Share		6.49
Cancellation of executive restricted stock, Range of Value per Share	12.50
Stock issued in conjunction with consulting/endorsement agreement, Range of Value per Share		5.85
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Stock issued to employees, executives and directors, Range of Value per Share	1.89	3.48
Total, Range of Value per Share	1.89	3.48
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock issued to employees, executives and directors, Range of Value per Share	2.95	8.60
Total, Range of Value per Share	$ 12.50	$ 8.60
Common Stock [Member] | Muscle Pharm Apparel [Member]
Class of Stock [Line Items]
Stock issued in conjunction with acquisition, Quantity		170,000
Stock issued in conjunction with acquisition, Valuation		$ 1,394
Stock issued in conjunction with acquisition, Range of Value per Share		$ 8.20

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Number of Treasury Shares, Acquired	0	0	0	0
Treasury Stock, shares	875,621		875,621		875,621
Treasury share used to secure promissory note					860,900

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Detail) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested Beginning Balance | shares	1,025,999
Number of Shares, Granted | shares	179,140
Number of Shares, Vested | shares	(609,139)
Number of Shares, Cancelled | shares	(260,000)
Number of Shares, Unvested Ending Balance | shares	336,000
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 12.34
Weighted-Average Grant Date Fair Value, Granted | $ / shares	2.17
Weighted-Average Grant Date Fair Value, Vested | $ / shares	11.55
Weighted-Average Grant Date Fair Value, Cancelled | $ / shares	13
Weighted-Average Grant Date Fair Value, Unvested Ending Balance | $ / shares	$ 7.69

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Feb. 29, 2016

Oct. 31, 2015

Aug. 31, 2015

Jul. 31, 2015

May 31, 2015

Feb. 28, 2015

Jan. 31, 2015

Sep. 30, 2014

Jul. 31, 2014

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2016

Jun. 30, 2015

Dec. 31, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards vesting period

24 months

Stock-based compensation

$ 5,097,000

$ 6,536,000

Total consideration related to the acquisition of the Apparel in cash

850,000

Loan amount outstanding

$ 13,348,000

13,348,000

$ 11,922,000

Consulting Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted common stock issued

30,000

Restricted stock, value

$ 402,000

ETW [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted common stock issued

446,853

Restricted stock, value

$ 5,000,000

ANB Bank [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Debt Instrument Maturity Date

Feb. 28, 2018

ANB Bank [Member] | Loan Modification Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Loan amount outstanding

$ 6,200,000

Debt Instrument Maturity Date

Jan. 15, 2016

Worldwide Apparel LLC [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total consideration related to the acquisition of the Apparel in cash

$ 850,000

Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued

170,000

Business Combination, Consideration Transferred, Equity Interests Issued and Issuable

$ 1,400,000

Finite-Lived Intangible Asset, Useful Life

7 years

Total cost of Apparel acquisition

$ 2,200,000

Energy Drink Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock awards issued related to financing agreement

150,000

Restricted stock awards grant date fair value

$ 1,200,000

Prepaid stock compensation amortization period

10 years

Prepaid stock compensation write down

$ 1,100,000

Brad Pyatt [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Severance cost

1,100,000

Lump sum payment for severance pay

$ 250,000

Unvested restricted stock awards, remaining number of shares

500,000

Brad Pyatt [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period for severance pay

12 months

Brad Pyatt [Member] | Salaries And Benefits [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock compensation expense

$ 3,900,000

Interim Chief Executive Officer, President and Chairman [Member] | ANB Bank [Member] | Loan Modification Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock issued to chairman of the board of directors, shares

28,571

Stock issued to chairman of the board of directors, value

$ 80,000

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards granted

100,000

$ 825,000

389,000

$ 900,000

Total unrecognized expense for unvested restricted stock awards

1,500,000

$ 1,500,000

$ 8,500,000

Total unrecognized expense for unvested restricted stock awards, weighted average period (in years)

2 years 2 months 12 days

3 years

Stock compensation expense written-off

3,800,000

Restricted Stock [Member] | Energy Drink Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards vesting period

3 years

Restricted Stock Awards Issued Related to Financing Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock awards issued related to financing agreement

50,000

Restricted stock awards grant date fair value

$ 325,000

Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock awards issued related to financing agreement

50,000

Restricted stock awards grant date fair value

$ 28,000

Prepaid stock compensation amortization period

3 years

Prepaid stock compensation write down

$ 268,000

Share issued within ten days after each subsequent three month period term

$ 25,000

Weighted average stock issuance prior period

15 days

Number of restricted stock awards issued related to consulting and endorsement agreement

5,189

Restricted Stock Awards Issued Related to Consulting/Endorsement Agreement [Member] | Additional Paid-In Capital [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock awards grant date fair value

$ 292,000

2015 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option plan, shares granted during period

0

Stock options contractual term

10 years

Fair value of options vested

$ 294,000

Restricted stock awards vesting period

2 years

Stock-based compensation

$ 41,000

$ 55,000

2015 Equity Incentive Plan [Member] | Interim Chief Executive Officer, President and Chairman [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option plan, shares granted during period

137,362

2015 Equity Incentive Plan [Member] | Lead Director of the Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option plan, shares granted during period

54,945

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net loss	$ (4,196)	$ (7,025)	$ (10,801)	$ (14,504)
Weighted-average common shares used in computing net loss per share, basic and diluted	13,874,209	13,647,267	13,855,754	13,491,433
Net loss per share, basic and diluted	$ (0.30)	$ (0.51)	$ (0.78)	$ (1.08)

Net Loss per Share - Antidiluti

Net Loss per Share - Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,237,002	2,309,193
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	192,307
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	100,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	336,000	2,309,193
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,608,695

Net Loss per Share - Antidilu63

Net Loss per Share - Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2016$ / shares
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 1.89
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	11.90
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 2.30

Endorsement Agreements - Additi

Endorsement Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended			6 Months Ended
	Jul. 31, 2014	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	May 30, 2016
Endorsement Agreement Disclosure [Line Items]
Asset impairment expense		$ 4,313,000			$ 4,313,000
Contractual obligation		8,236,000			$ 8,236,000
Warrants to purchase common stock	100,000
Weighted Average Exercise Price, Balance (in dollars per share)	$ 11.90
Warrants vesting period	24 months
Contractual term of warrants	5 years
Expected term (in years)					5 years
Fair value of warrants, assumption, risk free interest rate					1.70%
Fair value of warrants, assumption, dividend yield					0.00%
Fair value of warrants, assumption, expected volatility					55.00%
Warrant expense					$ 6,000	$ 50,000
Arnold Schwarzenegger Product Line [Member]
Endorsement Agreement Disclosure [Line Items]
Asset impairment expense					$ 1,900,000
Warrant [Member]
Endorsement Agreement Disclosure [Line Items]
Warrants vested					95,834
Advertising and Promotion Expense [Member]
Endorsement Agreement Disclosure [Line Items]
Warrant expense		3,000		$ 17,000	$ 6,000	$ 50,000
ETW [Member]
Endorsement Agreement Disclosure [Line Items]
Restricted common stock, shares issued value	$ 5,000,000
Prepaid Expense		3,500,000			3,500,000
Restricted common stock, shares issued	446,853
Contractual obligation							$ 2,200,000
Loss contingency accrual			$ 7,000,000		2,200,000
Restructuring expense		$ 4,800,000			4,800,000
Marine MP LLC [Member]
Endorsement Agreement Disclosure [Line Items]
Restricted common stock, shares issued value					$ 8,500,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 7	$ 21	$ 138	$ 33

Geographical Information - Reve

Geographical Information - Revenue, Net by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue, net:
Revenue, net	$ 32,867	$ 50,476	$ 75,779	$ 91,798
United States [Member]
Revenue, net:
Revenue, net	23,519	36,270	53,211	67,858
International [Member]
Revenue, net:
Revenue, net	$ 9,348	$ 14,206	$ 22,568	$ 23,940